Mode
Text Size
Log in / Sign up
N/A N=45 Treatment

Study on OsseoSpeed™ TX Short Implants in a Chinese Population

Partially Edentulous Jaw

Enrolled (actual)
45
Serious AEs
6.7%
Results posted
May 2019
Primary outcome: Primary: Marginal Bone Level Alteration — -0.06 millimeter

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
OsseoSpeed™ TX implant (Ø 4.0 mm, length 6 mm) (Device)
Age
Adult, Older Adult · 20+ yrs
Sex
All
Sponsor
Dentsply Sirona Implants and Consumables
Primary completion
Mar 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Marginal Bone Level Alteration
-0.06
SECONDARY
Marginal Bone Level Alteration After 36 Months
0.07
SECONDARY
Implant Survival
75
SECONDARY
Implant Stability
75
SECONDARY
Condition of the Periimplant Mucosa (PPD).
-0.63
SECONDARY
Condition of the Periimplant Mucosa (BoP).
43
SECONDARY
Plaque
29
SECONDARY
Crown-to-implant Ratio
1.70

Summary

The purpose of this study is to investigate the clinical efficacy of OsseoSpeed™ TX 6 mm implants in a Chinese population by evaluation of marginal bone level alteration, implant stability and implant survival in the posterior mandible and maxilla up to 3 years after loading. The hypothesis is that one stage surgery using 6 mm OsseoSpeed™ TX implant in the posterior region is safe and predictable.

Eligibility Criteria

Inclusion criteria

  • Provision of informed consent
  • Female and male aged 20-75 years at enrolment
  • In need for 2-3 implants in either side of the posterior mandible or maxilla (premolar and molar region)
  • History of edentulism in the study area of at least four months
  • Neighboring tooth/teeth to the planned bridge/crowns must have natural root(s)
  • Presence of natural teeth, partial prosthesis and/or implants in the opposite jaw in contact with the planned bridge/crowns
  • Deemed by the investigator to be suitable for implants of 6 mm length and to have a bone height of at least 6 mm and a bone width of minimum 6 mm
  • Deemed by the investigator as likely to present an initially stable implant situation

Exclusion criteria

  • Unlikely to be able to comply with study procedures, as judged by the investigator
  • Earlier graft procedures in the study area
  • Uncontrolled pathologic processes in the oral cavity
  • Known or suspected current malignancy
  • History of radiation therapy in the head and neck region
  • History of chemotherapy within 5 years prior to surgery
  • Systemic or local disease or condition that could compromise post-operative healing and/or osseointegration
  • Uncontrolled diabetes mellitus
  • Corticosteroids or any other medication that could influence post-operative healing and/or osseointegration
  • Smoking more than 10 cigarettes/day
  • Present alcohol and/or drug abuse
  • Involvement in the planning and conduct of the study (applies to both Astra Tech staff and staff at the study site)
  • Previous enrolment in the present study
  • Simultaneous participation in another clinical study, or participation in a clinical study during the last 6 months
  • Subjects that are unable to give informed consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01346696). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search